Device Trial Radar · NCT02310815
ReSure Sealant Post Approval Study
Last checked: Nov 20, 2026Latest source record: Dec 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
626
Actual
Start
Dec 2014
Primary completion
Feb 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 8, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective multicenter observational post-approval registry study that will collect post-approval data relative to the incidence of pre-specified Adverse Ocular Events for cataract surgery patients treated with the FDA-approved ReSure Sealant when used by a broad group of physicians under commercial use conditions.
Conditions
- Adverse Events
Interventions
ReSure SealantDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anterior chamber cells greater than level 1+ persisting at Visit 2 (≥ Day 20)Time frame: Post operative days 20 to 40
- Hypotony (≤ 5 mmHg)Time frame: Post operative days 20 to 40
- Ocular discomfortTime frame: Post operative days 20 to 40
1 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.